Serum anti-Mullerian hormone is associated with oocyte dysmorphisms and ICSI outcomes

Objective To evaluate the association between serum levels of anti-Mullerian hormone (AMH) and oocyte dysmorphisms in intracytoplasmic sperm injection (ICSI) cycles. Methods A retrospective study of data from 628 ICSI cycles with successful oocyte retrieval carried out at a single center in Tehran from November 2015 to July 2018. Cycles were divided into six groups by serum AMH level. Various oocyte dysmorphisms, quantity of retrieved oocytes, fertilization rates, cleavage-stage embryos, and pregnancy rates were compared among the groups. Results Serum AMH was associated with cytoplasm granulation, abnormally amorphous oocytes (P<0.01), extended perivitelline space (P<0.001), granulated perivitelline space (P<0.05), fragmented polar body (P<0.001), and average of oocyte quality index (AOQI) (P<0.01). The total number of aspirated and metaphase Iota Iota oocytes increased with increasing AMH levels (P<0.001). There was no difference in the rate of fertilization or cleavage-stage embryos among the study groups; however, the pregnancy rate differed significantly (P<0.05). Conclusions Serum levels of AMH were associated with specific oocyte dysmorphisms and AOQI. Serum AMH levels might influence both qualitative and quantitative aspects of the ovarian response to stimulation and also the pregnancy rate in ICSI cycles.